GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Moderna Inc (LIM:MRNA) » Definitions » Interest Coverage

Moderna (LIM:MRNA) Interest Coverage : 1.00 (As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Moderna Interest Coverage?

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. Moderna's Operating Income for the three months ended in Dec. 2023 was $6 Mil. Moderna's Interest Expense for the three months ended in Dec. 2023 was $-6 Mil. Moderna's interest coverage for the quarter that ended in Dec. 2023 was 1.00. The higher the ratio, the stronger the company's financial strength is.

The historical rank and industry rank for Moderna's Interest Coverage or its related term are showing as below:


LIM:MRNA's Interest Coverage is not ranked *
in the Biotechnology industry.
Industry Median: 127.155
* Ranked among companies with meaningful Interest Coverage only.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.


Moderna Interest Coverage Historical Data

The historical data trend for Moderna's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Moderna Interest Coverage Chart

Moderna Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Interest Coverage
Get a 7-Day Free Trial - - 738.67 324.83 -

Moderna Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Interest Coverage Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 158.00 - - - 1.00

Competitive Comparison of Moderna's Interest Coverage

For the Biotechnology subindustry, Moderna's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Moderna's Interest Coverage Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Moderna's Interest Coverage distribution charts can be found below:

* The bar in red indicates where Moderna's Interest Coverage falls into.



Moderna Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Interest Coverage=-1* Operating Income /Interest Expense

Else if Interest Expense is negative and Operating Income is negative, then

The company did not have earnings to cover the interest expense.

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

The company had no debt (1).


Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Moderna's Interest Coverage for the fiscal year that ended in Dec. 2023 is calculated as

Here, for the fiscal year that ended in Dec. 2023, Moderna's Interest Expense was $-38 Mil. Its Operating Income was $-4,239 Mil. And its Long-Term Debt & Capital Lease Obligation was $1,218 Mil.

Moderna did not have earnings to cover the interest expense.

Moderna's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as

Here, for the three months ended in Dec. 2023, Moderna's Interest Expense was $-6 Mil. Its Operating Income was $6 Mil. And its Long-Term Debt & Capital Lease Obligation was $1,218 Mil.

Interest Coverage=-1* Operating Income (Q: Dec. 2023 )/Interest Expense (Q: Dec. 2023 )
=-1*6/-6
=1.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's Financial Strength is.


Moderna  (LIM:MRNA) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .


Moderna Interest Coverage Related Terms

Thank you for viewing the detailed overview of Moderna's Interest Coverage provided by GuruFocus.com. Please click on the following links to see related term pages.


Moderna (LIM:MRNA) Business Description

Address
200 Technology Square, Cambridge, MA, USA, 02139
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its COVID-19 vaccine, which was authorized in the United States in December 2020. Moderna had 39 mRNA development candidates in clinical trials as of mid-2023. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.

Moderna (LIM:MRNA) Headlines

From GuruFocus

Moderna Inc at JPMorgan Healthcare Conference Transcript

By GuruFocus Research 01-23-2024

Q2 2023 Moderna Inc Earnings Call Transcript

By GuruFocus Research 01-23-2024

Moderna Inc Clinical Data Call Transcript

By GuruFocus Research 01-23-2024

Moderna Inc at Cowen Health Care Conference Transcript

By GuruFocus Research 01-23-2024

Moderna Inc R&D Day Transcript

By GuruFocus Research 01-23-2024

Moderna Inc to Host ESG Day Transcript

By GuruFocus Research 01-23-2024

Moderna Inc at UBS BioPharma Conference Transcript

By GuruFocus Research 01-23-2024